WO2000042973A3 - Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation - Google Patents

Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2000042973A3
WO2000042973A3 PCT/US2000/001602 US0001602W WO0042973A3 WO 2000042973 A3 WO2000042973 A3 WO 2000042973A3 US 0001602 W US0001602 W US 0001602W WO 0042973 A3 WO0042973 A3 WO 0042973A3
Authority
WO
WIPO (PCT)
Prior art keywords
homing
mammalian cell
methods
same
apoptotic
Prior art date
Application number
PCT/US2000/001602
Other languages
English (en)
Other versions
WO2000042973A2 (fr
Inventor
H Michael Ellerby
Dale E Bredesen
Renata Pasqualini
Erkki I Ruoslahti
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Priority to EP00911617A priority Critical patent/EP1150701A4/fr
Priority to CA002359633A priority patent/CA2359633A1/fr
Priority to AU33486/00A priority patent/AU770381B2/en
Priority to JP2000594432A priority patent/JP4531267B2/ja
Publication of WO2000042973A2 publication Critical patent/WO2000042973A2/fr
Publication of WO2000042973A3 publication Critical patent/WO2000042973A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un conjugué pro-apoptotique de domiciliation renfermant une molécule de ciblage de tumeur qui cible sélectivement un type déterminé de cellule ou de tissu de mammifère lié à un peptide anti-microbien. Ce conjugué est internalisé sélectivement par ce type de cellule ou ce tissu de mammifère, à l'égard duquel il manifeste une toxicité élevée. Le peptide antimicrobien a une faible toxicité à l'égard de la cellule de mammifère lorsqu'il n'est pas lié à la molécule de ciblage de la tumeur. Le conjugué pro-apoptotique selon l'invention peut être, par exemple, CNGRC-GG-D(KLAKLAK)2 ou ACDCRGDCFC-GG-D(KLAKLAK)2. Ces conjugués conviennent notamment pour le traitement d'un patient porteur d'une tumeur à vasculature angiogénique.
PCT/US2000/001602 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation WO2000042973A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00911617A EP1150701A4 (fr) 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation
CA002359633A CA2359633A1 (fr) 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation
AU33486/00A AU770381B2 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same
JP2000594432A JP4531267B2 (ja) 1999-01-22 2000-01-21 ホーミングプロアポトーシス結合体およびホーミングプロアポトーシス結合体を使用する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23590299A 1999-01-22 1999-01-22
US09/235,902 1999-01-22

Publications (2)

Publication Number Publication Date
WO2000042973A2 WO2000042973A2 (fr) 2000-07-27
WO2000042973A3 true WO2000042973A3 (fr) 2000-09-28

Family

ID=22887331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001602 WO2000042973A2 (fr) 1999-01-22 2000-01-21 Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1150701A4 (fr)
JP (1) JP4531267B2 (fr)
AU (1) AU770381B2 (fr)
CA (1) CA2359633A1 (fr)
WO (1) WO2000042973A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520808A (ja) * 2000-01-21 2003-07-08 ザ バーナム インスティチュート プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド
US20030166549A1 (en) * 2000-02-02 2003-09-04 Klaus Schughart Targeting peptides
WO2002020570A2 (fr) 2000-09-11 2002-03-14 Institut Pasteur Mecanisme de permeabilisation de la membrane mitochondriale via hiv-1 vpr, mimetiques de vpr, et methodes de criblage de molecules actives ayant la capacite de modifier et/ou d'empecher et/ou de mimer l'interaction de vpr avec ant
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
DE60230822D1 (de) * 2001-11-08 2009-02-26 Burnham Inst Peptide mit homing für lymphgefässtumor und ihre verwendung
EP1346729A1 (fr) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Cibler l'angiogénèse du myocarde à l'aide de CD13/APN
WO2004007557A2 (fr) * 2002-07-12 2004-01-22 Novo Nordisk A/S Antagoniste du facteur tissulaire
AU2004223546A1 (en) 2003-03-24 2004-10-07 Nippon Medical School Foundation Cell death-inducing fused gene acting specifically on cancer and gene product thereof
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005094383A2 (fr) * 2004-03-31 2005-10-13 Buck Institute Peptides chasseurs-tueurs et procedes d'utilisation
WO2006029343A2 (fr) * 2004-09-07 2006-03-16 The Burnham Institute Peptides ciblant selectivement le systeme cardio-vasculaire et conjugues et procedes associes
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
FI121959B (fi) 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
AU2009343754A1 (en) * 2009-04-01 2011-11-03 Ingo Schmidt-Wolf Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides
CA2795289A1 (fr) * 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methodes et compositions pour une administration amelioree de composes
WO2016172515A1 (fr) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Système d'administration ciblée et procédés d'utilisation correspondants
WO2017124147A1 (fr) * 2016-01-19 2017-07-27 The University Of Western Australia Nouveaux conjugués biomoléculaires et leurs utilisations
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018160791A1 (fr) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Constructions antimicrobiennes et leurs utilisations
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
EP4139327A4 (fr) * 2020-04-22 2024-10-02 Oncovolution Llc Complexes peptidique de platine et procédés d'utilisation associés
CN112830975B (zh) * 2021-02-02 2023-03-10 西南交通大学 α-螺旋构象稳定的促凋亡双环多肽及制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5928641A (en) * 1996-05-31 1999-07-27 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
CA2323071C (fr) * 1998-03-13 2011-06-21 The Burnham Institute Molecules se logeant dans divers organes ou tissus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5928641A (en) * 1996-05-31 1999-07-27 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAP ET. AL.: "Cancer Treatment by Target Drug Delivery to Tumor Vasculature in a Mouse Model", SCIENCE, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP002929458 *
ELLERBY ET. AL.: "Anti.-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP002929458 *
See also references of EP1150701A4 *

Also Published As

Publication number Publication date
EP1150701A2 (fr) 2001-11-07
AU770381B2 (en) 2004-02-19
EP1150701A4 (fr) 2003-03-26
WO2000042973A2 (fr) 2000-07-27
JP2002535258A (ja) 2002-10-22
CA2359633A1 (fr) 2000-07-27
JP4531267B2 (ja) 2010-08-25
AU3348600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
WO2000042973A3 (fr) Conjugues pro-apoptotiques de domiciliation et leurs methodes d'utilisation
CA2204535A1 (fr) Molecules qui se dirigent vers un organe ou des tissus choisis in vivo et procede d'identification desdites molecules
CA2255637A1 (fr) Conjugues d'acide cis-docosahexaenoique et de paclitaxel
HK1033466A1 (en) Molecules that home to various selected organs or tissues
CA2063886A1 (fr) Proteines conjuguees au polyethylene
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
CA2265484A1 (fr) Molecules se logeant dans une tumeur, conjugues tires de ces molecules et leurs procedes d'utilisation
CA2172513A1 (fr) Aminocyclohexylesters et leurs utilisations
EP2112161A3 (fr) Peptides abaissant les taux de glucose sanguin
CA2310850A1 (fr) Conjugat covalent de clozapine avec un acide gras et son utilisation pour traiter la schizophrenie
NZ503007A (en) Conjugates that contain the homeodomain of antennapedia
CA2174325A1 (fr) Conjugues polymeres ramifies non antigeniques
EP1724353A3 (fr) Méthode pour la formation de microparticules lipidiques couplées à des protéines
NO963283D0 (no) Ikke-viral vektor
WO2003068144A3 (fr) Agents cytotoxiques supportant une fraction reactive de polyethyleneglycol, conjugues cytotoxiques comprenant des groupes de liaison de polyethyleneglycol et leurs procedes de fabrication et d'utilisation
WO2002092620A3 (fr) Peptides et molecules apparentees se liant a tall-1
WO1998007745A3 (fr) Compositions et methodes pour traitement des infections, utilisant des analogues d'indolicidine
AU5242000A (en) Nematicidal trifluorobutenes
ZA979961B (en) 5-HT1F agonists
JP2002535258A5 (fr)
AU3037697A (en) Use of alpha-alkylglucosides and alpha-alkylglucoside esters as anti-microbial emulsifying agents
SG48889A1 (en) Bicycle-polyamacrocyclocarboxylic acid complexes conjugates preparation and use as contrast agents
AU3258197A (en) Peptides
AU5696298A (en) Keratinocyte growth factors and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2359633

Country of ref document: CA

Ref country code: CA

Ref document number: 2359633

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 594432

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 33486/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000911617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000911617

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33486/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 2000911617

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000911617

Country of ref document: EP